Recent Finacing
Recent Raise
Osivax is a biotech developing pan‑respiratory vaccines using its oligoDOM self‑assembling nanoparticle platform targeting conserved nucleoprotein antigens; lead candidate OVX836 is advancing through Phase‑2 clinical and field efficacy trials.
